The US is the leading destination market for greenfield biotechnology FDI, while it is also the top source market. GlobalData’s biotechnology foreign direct investment (FDI) report highlights the current trends in biotechnology foreign investments. Buy the report here.
Between 2019 and 2022, the biotechnology sector was the twenty-fifth largest FDI sector in terms of the number of greenfield investments. The biotechnology sector accounts for 0.6% of global greenfield FDI projects.
Greenfield foreign direct investment is when a company invests abroad to establish a new physical presence or expand an existing operation. Greenfield investments create jobs and/or involve a capital investment into the foreign location. Other forms of FDI, such as mergers and acquisitions, are not included as part of this definition.
Combined, the top ten destination countries account for 69.2% of total biotechnology FDI projects.
The leading destination country for biotechnology FDI is the US. Germany, the UK and China are also popular biotechnology investment hubs.
According to GlobalData’s FDI Projects database, Japan-based companies were the leading source of greenfield biotechnology investments into the US.
With respect to outbound FDI, the US was the leading biotechnology source market. US-based companies held a 29.7% share of total outbound biotechnology FDI projects. Japan, Germany, China and the UK are also top source markets for biotechnology FDI.
To further understand global biotechnology foreign direct investment trends, buy the report here.